Visionary Venture Fund
VC Fund
Aliso Viejo, United States
Visionary Venture Fund is a VC fund in Aliso Viejo focused on Health Care and Medical Device. Visionary is a venture capital firm that invests in the most promising emerging ophthalmology companies in medical devices and pharmaceuticals.With many breakthrough ophthalmic technologies and platforms on the horizon, Visionary Venture Fund was created to help these companies by contributing clinical expertise, commercialization know-how, andgrowth capital. We work hand-in-hand with today's most promising ophthalmic technologies to create tomorrow's commercial blockbusters.We're looking for visionary entrepreneurs, proven teams, and strong IP to create exciting ideas that address large unmet needs in ophthalmology in order to create market-leading businesses. We are a focused venture capital fund from round A to commercialization. Our target investments range from $500K to $5M in financing rounds ranging from $5M to $15MM. We seek to be lead investors and a partner of choice in our deals as we bring a strong KOL doctor partnership to the table. Visionary’s fund performance net of fees is a 30% IIR, which places it in the top decile of US venture funds.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Visionary Venture Fund invests in
Stages Visionary Venture Fund invests in
Countries Visionary Venture Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Garrett Hamontree
|
|||
Jeffry Weinhuff
|
|||
Investment Focus
Industry
- Health Care 12 (44%)
- Medical Device 7 (26%)
- Medical 6 (22%)
- Biotechnology 6 (22%)
- Pharmaceutical 6 (22%)
Stage
- Series B 10 (37%)
- Series A 6 (22%)
- Series C 4 (15%)
- Seed 1 (4%)
- Series D 1 (4%)
Country
- United States 14 (52%)
- Israel 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Garrett Hamontree
Principal
|
Principal | Total investments: 2 | Find email | |
Gregory Wertman
Limited Partner
|
Limited Partner | Total investments: 0 | Find email | |
|
Jeffry Weinhuff
Managing Partner
|
Managing Partner | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $120M / Series B / Oct 15, 2025 | |
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M / Series C / Aug 20, 2025 | |
Orasis Pharmaceuticals
|
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M / Series D / Oct 08, 2024 | |
|
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $14M / Series A / Aug 13, 2024 | |
|
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $16.8M / Series A / Feb 27, 2024 | |
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M / Series C / Mar 08, 2023 | |
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
|
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
|
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $23M / Series B / Aug 30, 2022 | |
Aurion Biotechnologies
|
Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinicallyvalidated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness. | $120M / Venture - Series Unknown / Apr 12, 2022 | |
| See all 27 investments → | |||
Co-Investors
ExSight Ventures
13 deals together
Bluestem Capital
7 deals together
Google Ventures
6 deals together
InFocus Capital Partners
6 deals together
QUBIS
4 deals together
Techstart Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Visionary Venture Fund invest in?
Visionary Venture Fund invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Visionary Venture Fund?
Public channels for Visionary Venture Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Visionary Venture Fund?
The team at Visionary Venture Fund includes Garrett Hamontree (Principal), Gregory Wertman (Limited Partner) and Jeffry Weinhuff (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
